The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 5 , Pages 1036-1041 , May 2008

Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non–small cell lung cancer

  • Daniela Kandioler, MD

      Affiliations

    • Division of Surgery, Medical University of Vienna, Austria
    • Division of Surgical Research, Medical University of Vienna, Austria
    • Corresponding Author InformationAddress for reprints: Daniela Kandioler, MD, MBA, Division of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
    • ,
  • Georgios Stamatis, MD

      Affiliations

    • Division of Thoracic Surgery, Ruhrland Klinik, Essen-Heidhausen, Germany
    • ,
  • Wilfried Eberhardt, MD

      Affiliations

    • Division of Internal Medicine, University of Essen, Germany
    • ,
  • Sonja Kappel, PhD

      Affiliations

    • Division of Surgical Research, Medical University of Vienna, Austria
    • ,
  • Sabine Zöchbauer-Müller, MD

      Affiliations

    • Division of Internal Medicine, Medical University of Vienna, Austria
    • ,
  • Irene Kührer, MD

      Affiliations

    • Division of Internal Medicine, Medical University of Vienna, Austria
    • ,
  • Martina Mittlböck, PhD

      Affiliations

    • Section of Clinical Biometrics, Medical University of Vienna, Austria
    • ,
  • Ronald Zwrtek, MD

      Affiliations

    • Division of Surgery, Landesklinikum St Pölten, Austria
    • ,
  • Clemens Aigner, MD

      Affiliations

    • Division of Thoracic Surgery, Medical University of Vienna, Austria
    • ,
  • Christoph Bichler, JD

      Affiliations

    • Division of Surgical Research, Medical University of Vienna, Austria
    • ,
  • Victoria Tichy, JD

      Affiliations

    • Division of Surgical Research, Medical University of Vienna, Austria
    • ,
  • Marcus Hudec, PhD

      Affiliations

    • Department of Scientific Computing, University of Vienna, Austria
    • ,
  • Thomas Bachleitner, MD

      Affiliations

    • Division of Surgery, Medical University of Vienna, Austria
    • ,
  • Adelheid End, MD

      Affiliations

    • Division of Thoracic Surgery, Medical University of Vienna, Austria
    • ,
  • Michael Rolf Müller, MD

      Affiliations

    • Division of Thoracic Surgery, Medical University of Vienna, Austria
    • ,
  • Erich Roth, PhD

      Affiliations

    • Division of Surgical Research, Medical University of Vienna, Austria
    • ,
  • Walter Klepetko, MD

      Affiliations

    • Division of Thoracic Surgery, Medical University of Vienna, Austria

Received 2 May 2007 ,Revised 26 September 2007 ,Accepted 22 October 2007.

References 

  1. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep. 2004;12:955–965
  2. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  3. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1–6
  4. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158
  5. Rosell R, Gomez-Codina J, Camps C, Javier Sanchez J, Maestre J, Padilla J, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer. 1999;26:7–14
  6. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–1215
  7. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198–205
  8. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–1937
  9. Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies?. Anticancer Drugs. 2000;11:419–432
  10. Peller S. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Semin Cancer Biol. 1998;8:379–387
  11. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–967
  12. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci. 1999;55:28–37
  13. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807–810
  14. Lai SL, Perng RP, Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci. 2000;7:64–70
  15. Bergqvist M, Brattstrom D, Gullbo J, Hesselius P, Brodin O, Wagenius G. p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer. Anticancer Res. 2003;23(2B):1207–1212
  16. Kandioler-Eckersberger D, Kappel S, Mittlbock M, Dekan G, Ludwig C, Janschek E, et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg. 1999;117:744–750
  17. Kandioler D. p53 as a prognostic and predictive indicator. In:  Gasparini G,  Hayes F editor. Biomarkers in Breast Cancer Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect. Totowa: Humana Press; 2005;p. 193–209
  18. Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer. 2006;118:396–404
  19. Stamatis G, Eberhardt W, Stuben G, Bildat S, Dahler O, Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg. 1999;68:1144–1149
  20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  22. Klingler A. Statistical methods in surgical research—a practical guide. Eur Surg. 2004;36:80–84
  23. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun. 2005;331:868–880
  24. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705–719
  25. d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:352–363
  26. vom Brocke J, Schmeiser HH, Reinbold M, Hollstein M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis. 2006;27:2141–2147

 Presented in part at the Forty-first Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13-15, 2005.

 Supported by national grant: Medizinisch wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien, number 2495.

PII: S0022-5223(07)01992-7

doi: 10.1016/j.jtcvs.2007.10.072

The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 5 , Pages 1036-1041 , May 2008

Article Tools

* Image Usage & Resolution